Compare AstraZeneca plc (AZN) vs Harmony Gold Mining Co. (HMY) Price & Performance

AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.

The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.

Harmony Gold Mining (HMY) trades at $14.99, down 0.79% on the day, with a bearish technical signal from moving averages. The company shows strong fundamentals with 2024 revenue of $61.38 billion and net income of $8.59 billion, yielding robust profitability margins. Recent earnings were mixed, beating in Q2 2025 but missing in Q4 2025. Analyst sentiment is cautious with 70% hold ratings, while news highlights stock volatility tied to gold price sensitivity and Fed policy expectations.

HMY presents a valuation opportunity with low P/E (9.59) and EV/EBITDA (5.05) multiples, supported by high ROE (32.32%) and a 4.06% dividend yield. Key risks include gold price exposure, operational execution in its pivot to gold-copper hybrid model, and macroeconomic headwinds from potential interest rate hikes. Institutional consensus leans neutral, suggesting patience for copper project contributions to justify higher multiples.